Intellia Therapeutics (NTLA) Misses Q1 EPS by 19c, Revenues Miss

Intellia Therapeutics (NASDAQ: NTLA) reported Q1 EPS of ($0.63), $0.19 worse than the analyst estimate of ($0.44). Revenue for the quarter came in at $12.92 million versus the consensus estimate of $18.14 million.

“At Intellia, our mission is to develop curative, CRISPR/Cas9-based treatments for severe diseases. I am grateful to our team for remaining steadfast in our commitment to patients and putting us in the position to deliver on our goals despite the challenging circumstances presented by the global COVID-19 pandemic,” said Intellia President and Chief Executive Officer John Leonard, M.D. “We look forward to advancing NTLA-2001 into clinical testing and dosing ATTR patients with the first systemically delivered CRISPR/Cas9-based therapy in the second half of 2020. Additionally, we continue to advance our full-spectrum pipeline, including IND-enabling activities for NTLA-5001, our engineered TCR-T cell therapy candidate for AML, and the nomination of NTLA-2002 as our development candidate for the treatment of HAE.”

Financial Guidance

Intellia expects that its cash, cash equivalents and marketable securities as of March 31, 2020 will enable the Company to fund its anticipated operating expenses and capital expenditure requirements at least through the end of 2021. This expectation excludes any strategic use of capital not currently in the Company’s base-case planning assumptions.

For earnings history and earnings-related data on Intellia Therapeutics (NTLA) click here.

You May Also Be Interested In

• Alphabet (GOOGL) soars 16% on Q1 results beat, first-ever dividend
• SPS Commerce (SPSC) Tops Q1 EPS by 12c
• Northeast Community Bancorp, Inc. (NECB) Tops Q1 EPS by 12c